NOVEN ANNOUNCES COMMENCEMENT OF PHASE 2 STUDY OF INVESTIGATIONAL d-AMPHETAMINE TRANSDERMAL SYSTEM FOR ADHD October 2, 2012 − Miami, FL and New York, NY − Noven Pharmaceuticals, Inc., a whollyowned subsidiary of Hisam

First Page		Document Content
Date: 2013-06-27 13:51:08		NOVEN ANNOUNCES COMMENCEMENT OF PHASE 2 STUDY OF INVESTIGATIONAL d-AMPHETAMINE TRANSDERMAL SYSTEM FOR ADHD October 2, 2012 − Miami, FL and New York, NY − Noven Pharmaceuticals, Inc., a whollyowned subsidiary of Hisam Add to Reading List Source URL: www.noven.com Download Document from Source Website File Size: 170,49 KB Share Document on Facebook